Antimicrobial stewardship is a coordinated set of activities that promote the appropriate use of antimicrobial medicines: the right drug, at the right dose, by the right route, for the right duration, and only where a bacterial or other treatable infection is genuinely likely. Its purpose is to improve individual patient outcomes while preserving the long-term effectiveness of a shared and finite resource.
Antimicrobial resistance develops when organisms evolve to survive exposure to the drugs designed to kill them. Every unnecessary or overlong course applies selection pressure. The consequences are already visible in resistant bloodstream infections, resistant tuberculosis and multi-drug resistant gram-negative organisms, and the pipeline of genuinely novel antibiotics remains thin.
UK practice is often summarised as Start Smart Then Focus. Start Smart means not starting antimicrobials without clinical evidence of infection, taking cultures before the first dose where possible, documenting the indication, dose and planned duration in the notes, and following local rather than generic prescribing guidance. Then Focus means a formal review at 48 to 72 hours with a documented decision.
Stewardship programmes are underpinned by surveillance: total consumption data, the proportion of prescribing that falls into the WHO Access, Watch and Reserve categories, compliance with local guidelines and resistance rates over time. Electronic prescribing systems, decision support that surfaces local sensitivities at the point of prescribing, and rapid diagnostics that shorten the window of empirical treatment all contribute directly to stewardship goals.
.svg)
